Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 259


Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis.

Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, Dougados M, Sibilia J, Le Loet X, Dieudé P.

RMD Open. 2017 Sep 28;3(2):e000448. doi: 10.1136/rmdopen-2017-000448. eCollection 2017.


Soluble vascular endothelial (VE) cadherin and autoantibodies to VE-cadherin in rheumatoid arthritis patients treated with etanercept or adalimumab.

Banse C, Polena H, Stidder B, Khalil-Mgharbel A, Houivet E, Lequerré T, Fardellone P, Le-Loët X, Philippe P, Marcelli C, Vittecoq O, Vilgrain I.

Joint Bone Spine. 2017 Dec;84(6):685-691. doi: 10.1016/j.jbspin.2016.10.012. Epub 2016 Nov 25.


Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.

Granger B, Combe B, Le Loet X, Saraux A, Guillemin F, Fautrel B.

RMD Open. 2016 May 20;2(1):e000245. doi: 10.1136/rmdopen-2016-000245. eCollection 2016.


Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.

Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Le Loët X, Shaeverbeke T, Ravaud P, Mariette X, Gottenberg JE; French Society of Rheumatology.

Rheumatology (Oxford). 2016 May;55(5):874-82. doi: 10.1093/rheumatology/kev437. Epub 2016 Jan 27.


Early phase clinical and biological markers associated with subclinical atherosclerosis measured at 7 years of evolution in an early inflammatory arthritis cohort.

Vandhuick T, Allanore Y, Borderie D, Louvel JP, Fardellone P, Dieudé P, Goëb V, Clavel G, Boissier MC, Jouen F, Boumier P, Allart JD, Mejjad O, Pouplin S, Jan M, Ménard JF, Le Loët X, Vittecoq O.

Clin Exp Rheumatol. 2016 Jan-Feb;34(1):58-67. Epub 2015 Dec 20.


Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors.

Golinski ML, Vandhuick T, Derambure C, Fréret M, Lecuyer M, Guillou C, Hiron M, Boyer O, Le Loët X, Vittecoq O, Lequerré T.

Arthritis Res Ther. 2015 Dec 26;17:382. doi: 10.1186/s13075-015-0894-9.


Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients.

Gossec L, Danré A, Combe B, Le Loët X, Tebib J, Sibilia J, Mariette X, Dougados M.

Joint Bone Spine. 2015 Dec;82(6):451-4. doi: 10.1016/j.jbspin.2015.02.007. Epub 2015 Jul 7.


Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.

Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, Houvenagel E, Gaudin P, Loeuille D, Rist S, Dougados M, Sibilia J, Le Loët X, Meyer O, Solau-Gervais E, Marcelli C, Bardin T, Pane I, Baron G, Perrodeau E, Mariette X; all the investigators of the ORA registry and the French Society of Rheumatology.

Ann Rheum Dis. 2016 Jun;75(6):1108-13. doi: 10.1136/annrheumdis-2015-207362. Epub 2015 Jun 5.


Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.

Lequerré T, Farran É, Ménard JF, Kozyreff-Meurice M, Vandhuick T, Tharasse C, Pouplin S, Daragon A, Le Loët X, Varin R, Vittecoq O.

Joint Bone Spine. 2015 Oct;82(5):330-7. doi: 10.1016/j.jbspin.2015.01.021. Epub 2015 Apr 10.


Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach.

Obry A, Lequerré T, Hardouin J, Boyer O, Fardellone P, Philippe P, Le Loët X, Cosette P, Vittecoq O.

PLoS One. 2014 Dec 29;9(12):e115800. doi: 10.1371/journal.pone.0115800. eCollection 2014.


Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study.

Trouvin AP, Jacquot S, Grigioni S, Curis E, Dedreux I, Roucheux A, Boulard H, Vittecoq O, Le Loët X, Boyer O, Goëb V.

Clin Exp Immunol. 2015 Apr;180(1):11-8. doi: 10.1111/cei.12481.


Validation of the 2010-ACR/EULAR -classification criteria using newly EULAR-defined erosion for rheumatoid arthritis on the very early arthritis community-based (VErA) cohort.

Le Loët X, Nicolau J, Boumier P, Daragon A, Mejjad O, Pouplin S, Zarnitsky C, Vittecoq O, Fardellone P, Ménard JF.

Joint Bone Spine. 2015 Jan;82(1):38-41. doi: 10.1016/j.jbspin.2014.03.008. Epub 2014 Oct 7.


Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.

Payet S, Soubrier M, Perrodeau E, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Le Loët X, Shaeverbeke T, Ravaud P, Gottenberg JE, Mariette X.

Arthritis Care Res (Hoboken). 2014 Sep;66(9):1289-95.


Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.

Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, Le Loët X, Vittecoq O, Goupille P, Mulleman D, Paintaud G.

Br J Clin Pharmacol. 2015 Feb;79(2):286-97. doi: 10.1111/bcp.12509.


Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry.

Couderc M, Gottenberg JE, Mariette X, Pereira B, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Le Loët X, Shaeverbeke T, Ravaud P, Soubrier M; Club Rhumatismes et Inflammations.

Rheumatology (Oxford). 2014 Oct;53(10):1788-93. doi: 10.1093/rheumatology/keu176. Epub 2014 May 11.


Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial.

Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon HJ, Rouanet S, Taoufik Y, Hendel-Chavez H, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Chiocchia G.

Arthritis Rheumatol. 2014 Aug;66(8):2015-25. doi: 10.1002/art.38671.


Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice.

Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, Logeart I, Schaeverbeke T, Sibilia J, Le Loët X, Combe B.

Joint Bone Spine. 2014 Jul;81(4):352-9. doi: 10.1016/j.jbspin.2014.02.014. Epub 2014 Apr 8.


Towards an individualised target concentration of adalimumab in rheumatoid arthritis.

Ducourau E, Ternant D, Lequerré T, Fuzibet P, Le Loët X, Watier H, Goupille P, Paintaud G, Vittecoq O, Mulleman D.

Ann Rheum Dis. 2014 Jul;73(7):1428-9. doi: 10.1136/annrheumdis-2013-204971. Epub 2014 Feb 18. No abstract available.


Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene.

Gazal S, Sacre K, Allanore Y, Teruel M, Goodall AH; (The CARDIOGENICS consortium), Tohma S, Alfredsson L, Okada Y, Xie G, Constantin A, Balsa A, Kawasaki A, Nicaise P, Amos C, Rodriguez-Rodriguez L, Chiocchia G, Boileau C, Zhang J, Vittecoq O, Barnetche T, Gonzalez Gay MA, Furukawa H, Cantagrel A, Le Loët X, Sumida T, Hurtado-Nedelec M, Richez C, Chollet-Martin S, Schaeverbeke T, Combe B, Khoryati L, Coustet B, El-Benna J, Siminovitch K, Plenge R, Padyukov L, Martin J, Tsuchiya N, Dieudé P.

Ann Rheum Dis. 2015 Mar;74(3):e19. doi: 10.1136/annrheumdis-2013-204581. Epub 2014 Jan 21.


Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.

Combe B, Rincheval N, Benessiano J, Berenbaum F, Cantagrel A, Daurès JP, Dougados M, Fardellone P, Fautrel B, Flipo RM, Goupille P, Guillemin F, Le Loët X, Logeart I, Mariette X, Meyer O, Ravaud P, Saraux A, Schaeverbeke T, Sibilia J.

J Rheumatol. 2013 Oct;40(10):1650-7. doi: 10.3899/jrheum.121515. Epub 2013 Aug 15.


Supplemental Content

Loading ...
Support Center